natgillin/translations-raw huggingface dataset:
The transgenic mouse of claim 15, wherein the human Vk-Jk intergenic region sequence comprises SEQ ID NO: 100. A mouse cell comprising in its genome an endogenous λ light chain immunoglobulin locus comprising a deletion of the endogenous mouse Vλ1-Jλ3-Cλ3-Jλ1-Cλ1 gene cluster and a deletion of a region spanning from Vλ2 to Jλ2 of the endogenous mouse Vλ2-Vλ3-Jλ2-Cλ2-Jλ4-Cλ4 gene cluster. 
Mišja stanica koja u svom genomu sadrži endogeni lokus imunoglobulina lakog lanca A koji se sastoji od brisanja endogenog mišjeg VM -JX43-C23-JM-CM klastera gena 1 brisanja regije koja se proteže od VA2 do JM2 endogenog mišjeg VA2-V23-JX2-C12-IA4-CI4 klastera gena, naznačena time, što endogeni lokus imunoglobulina lakog lanca X zadržava endogene C22, JA4 1 CH4 genske segmente.
The pharmaceutical composition according to claims 8 to 12, wherein the TNFa inhibitor is an anti-TNFa antibody. A kit comprising 
Farmaceutski pripravak u skladu s patentnim zahtjevima 8 do 12, naznačen time, da TNFa inhibitor je protu-TNFa protutijelo.
The compound for use as defined in claim 34, wherein the pain inflammatory pain, neuropathic pain, pain associated with cancer, pain associated with surgery or pain associated with bone fracture. 
Spoj za uporabu prema zahtjevu 34, gdje je bol upalna bol, neuropatska bol, bol povezana s rakom, bol povezana s operacijom ili bol povezana s prijelomom kosti.
A data node is distinguished in that the user data that is associated with a terminal is stored in said data node, with this storage being carried out associated with the hash value of the identifier of this terminal. 
Telekomunikacijska mreža (T) temeljem zahtjeva 8 ili 9, naznačena time što se korisnički podaci povezani sa hash vrijednošću pohranjuju u podatkovnom čvorištu (DNDR), a adresa, povezana sa hash vrijednošću, tog podatkovnog čvorišta (DNDR) koja drži korisničke podatke povezane sa hash vrijednošću, je pohranjena u lokalizacijskom čvorištu (DNLR).
The use of claim 11, wherein the skeletal muscular disorders and diseases are selected from the group consisting of skeletal muscle fatigue, exercise-induced skeletal muscle fatigue, muscular dystrophy, bladder disorders, and incontinence. 
Spoj prema patentnom zahtjevu 11, naznačen time što su poremećaji i bolesti skeletnih mišića izabrani iz grupe koju čine zamor skeletnog mišića, zamor skeletnog mišića izazvan pojačanom fizičkom aktivnošću, mišićna distrofija, poremećaji bešike 1 inkontinencija.
The reaction mixture was refluxed for 1 hour. 
Reakcijska smjesa je refluksirana kroz 1 sat.
said compression limiter is disparate from said annular metal seal element and is coated with dielectric material. The isolation system of claim 1, wherein said isolating washer further comprises a metal washer having opposing side surfaces with a sheet of dielectric material laminated to one of said opposing side surfaces and wherein said isolating washer is receivable on at least one elongate metal fastener with said laminated dielectric material abutting at least one outer face of said flange pieces. 
Izolacijski sustav prema zahtjevu 1, naznačen time, da spomenuti izolacijski zaporni prsten (26) nadalje obuhvaća metalni zapornik koji ima nasuprotne bočne površine s pločicom dielektričnog materijala laminiranog na jednu od nasuprotnih bočnih površina i pri čemu se spomenuti izolacijski zaporni prsten (26) može prihvaćati na najmanje jednom izduženom metalnom pričvršćivaču (18) sa spomenutim laminiranim dielektričnim materijalom koji dodiruje najmanje jednu od vanjskih fronta (24) spomenutog dijela šarki.
A hydrate form of the salt according to claim 1. 
Spoj, naznačen time, da je hidratni oblik soli u skladu sa zahtjevom 1.
The composition of claim 1, in which the policosanol is selected from the group consisting of triacontanol, hexacosanol, hexacontanol, ecocontanol, tetracosanol, dotriacontanol, and tetracontanol. 
Pripravak u skladu s patentnim zahtjevom 1, naznačen time što se polikozanol koji sadrži bira iz skupine koju čine triakontanol, heksakozanol, heksakontanol, ekokontanol, tetrakozanol, dotriakontanol i tetrakontanol.
A combination of a compound of claim 2 and a further drug. 
Kombinacija spoja koji je spoj koji ima strukturu:
a compound of formula I wherein R1 is difluoromethyl or trifluoromethyl and X is chloro, fluoro or bromo; and the compound fenpropidin. 
CH, naznačen time da je Ry difluorometil ili trifluorometil, a X kloro, fluoro, ili bromo; i (B) spoj klorotalonil.
from 40% to 75% by weight of microcrystalline cellulose; 
(c) od 40% do 75% težinski mikrokristalinične celuloze;
The formulations may conveniently be presented in unit dosage form by methods known to those skilled in the art. 
Formulacija se može prezentirati u jednoj doznoj jedinici metodama koje su poznate osobama iz struke.
5 . Preferably the additional oligonucleotide binds to the strand released by the IO and branch migrates into the proximal duplex nucleic acid. 
Komplet iz patentnog zahtjeva 7 pri čemu se dodatni oligonukleotid veže na lanac koji je ispustio oligonukleotid i grana se pomjera u proksimalnu dupleks nukleinsku kiselinu.
An object of the present invention is therefore that of providing a steel strip of the above-mentioned type which, unlike the other cold rolled dual phase steels being known so far, has the same features and may replace without problems a cold rolled dual phase steel strip, in particular for cold pressed or cut pieces. 
Cilj ovog izuma je prema tome osigurati čeličnu traku prethodno navedenog tipa koja, za razliku od drugih hladno valjanih dvofaznih čelika koji su poznati do sada, ima iste karakteristike i može bez problema zamijeniti hladno valjanu dvofaznu čeličnu traku, posebno za hladno prešane ili izrezane komade.
a capture tag agent of formula (III) Z-Y-XH (III) wherein X, Z and Y are defined as in any one of claims 1-9, and a capture reagent capable of interacting with the capture tag, wherein the capture reagent is selected from the group consisting of a solid phase of a standard reverse phase chromatography such as RP-HPLC, a chromatographic material with affinity for hydrophobic groups, a chromatographic material with affinity for fluorinated groups such as a fluorous affinity support, a capture reagent containing an alkynyl moiety, and a capture reagent containing an azido moiety. 
(a) sredstvo koje je oznaka za hvatanje formule (III) Z-Y-XH (ID gdje su X, Z 1 Y kako su definirani prema bilo kojem od zahtjeva 1-9, i (b) reagens za hvatanje koji može stupiti u interakciju s oznakom za hvatanje, gdje se reagens za hvatanje odabire iz grupe koju čine kruta faza standardne reverzno fazne kromatografije kao RP-HPLC, kromatografski materijal s afinitetom za hidrofobne skupine, kromatografski materijal s afinitetom za fluorinirane skupine kao fluorna afinitetna podloga, reagens za hvatanje koji obuhvaća alkinil skupinu, 1 reagens za hvatanje koji obuhvaća azido skupinu.
The composition of Claim 2, additionally comprising a second therapeutic agent selected from a second HIV protease inhibitor, a non-nucleoside reverse transcriptase inhibitor, a nucleoside/nucleatide reverse transcriptase inhibitor, a viral entry inhibitor, an integrase inhibitor, an immune based antiretroviral agent, a viral maturation inhibitor, a cellular inhibitor, or combinations of two or more of the above. 
Kompozicija prema zahtjevu 7 ili zahtjevu 8, koja dodatno sadrži drugo terapeutsko sredstvo koje se bira od drugog inhibitora HIV proteaze, nenukleozidnog inhibitora reverzne transkriptaze, nukleozid-nog/nukleotidnog inhibitora reverzne transkriptaze, inhibitora ulaza virusa, inhibitora integraze, antiretroviralnog imunološkog sredstva, inhibitora sazrijevanja virusa, staničnog inhibitora, ili od kombinacija dva ili više gore navedenih.
(substituent group C is as defined in item 13′ or item 13). 
(pri čemu Supstituentska skupina C ima isto značenje kao što je navedeno u zahtjevu 13).
The reaction mixture is diluted with water (3 ml) and extracted with ether (3×15 ml). 
Reakcijsku smjesu se razrijedi s vodom (3 ml) 1 ekstrahira s eterom (3 x 15 ml).
and pharmaceutically acceptable salts thereof. Compounds according to claim 1 wherein the carbon atom bound to the phenyl ring of formula I is in S configuration. 
i njihove farmaceutski prihvatljive soli, pri čemu je ugljikov atom vezan na fenilni prsten formule (I) S konfiguracije.
wherein the enzyme is adapted to enantioselectively hydrolyze the compound of Formula 4 to the compound of Formula 3 or a salt thereof; 
R*O;C gdje enzim je prilagođen tako da enantioselektivno hidrolizira spoj Formule 4 u spoj Formule 3, ili njegovu sol;
A pharmaceutical composition comprising a therapeutically effective amount of the compound of any one of Claims 1 to 14 and a pharmaceutically acceptable carrier. 
Farmaceutski pripravak, naznačen time, da sadrži terapijski učinkovitu količinu spoja iz bilo kojeg od Patentnih zahtjeva 1 do 14 1 farmaceutski prihvatljiv nosač.
mL of filtrate was collected and applied to a 70 g, 5×6.5 cm C18-RP SPE bed (Supelco® LC-18 material) that had been conditioned with 50% (v/v) ethanol/water and percolated with 200 mL distilled water before usage. 
150 mL filtrata se sakupi i nanese na 70 g, 5 x 6,5 cm C18-RP SPE ploču (Supelco" LC-18 materijal) koja je kondicionirana s 50%-tnim (v/v) etanolom/vodom i perkolirana s 200 mL destilirane vode prije upotrebe.
or a pharmaceutically-acceptable salt thereof. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1 and a pharmaceutically acceptable carrier. 
Farmaceutski pripravak, naznačen time, da sadrži terapijski učinkovitu količinu spoja iz bilo kojeg od Patentnih zahtjeva 1 do 14 1 farmaceutski prihvatljiv nosač.
The antibody of any one of items 14-18, wherein the antibody comprises the framework residues of CH1A1A (SEQ ID NO: 261) or CH1A1B (SEQ ID NO: 262). 
Protutijelo u skladu s patentnim zahtjevom 1, naznačeno time, da protutijelo obuhvaća okvirne ostatke CHIA1A (SEQ ID NO: 261) ili CHIA1B (SEQ ID NO: 262).
The feed stock of claim 14, wherein the sorbent is selected from the group consisting of trisodium hydrogendicarbonate dehydrate (Trona), sodium bicarbonate, sodium carbonate, zinc ferrite, zinc copper ferrite, zinc titanate, copper ferrite aluminate, copper aluminate, copper manganese oxide, nickel supported on alumina, zinc oxide, iron oxide, copper, copper (I) oxide, copper (II) oxide, limestone, lime, Fe, FeO, Fe2O3, Fe3O4, iron filings, CaCO3, Ca(OH)2, CaCO3, MgO, silica, alumina, china clay, kaolinite, bauxite, emathlite, attapulgite, calcium magnesium acetate, coal ash, egg shells, and Ca-montmorillonite. 
HR P20170938 T1 oksid, bakar, bakrov (I) oksid, bakrov (II) oksid, vapnenac, vapno, Fe, FeO, Fe,O:3, Fe:04, željezna strugotina, CaCO>s, Ca (OH) 2, CaCOs5 x MgO, silicijev dioksid, aluminijev oksid, kaolin, kaolinit, boksit, ematlit, atapulgit, ugljeni pepel, ljuska jajeta i Ca-montmorilonit. Postupak u skladu s patentnim zahtjevom 8 ili modificirano zamjensko gorivo u skladu s patentnim zahtjevom 3, naznačeno time, da je jedan od dva ili više sorbensa trinatrij hidrogendikarbonat dihidrat (Trona).
Use of the polypeptide according to one or more of claims 1 to 8 or 21 to 26 or of the composition of claim 26 for the enzymatic degradation of lignocellulosic biomass, and/or for textiles processing and/or as ingredient in detergents and/or as ingredient in food or feed compositions. 
Upotreba polipeptida u skladu s jednim ili više patentnih zahtjeva 1 do 9 ili pripravka u skladu s patentnim zahtjevom 13, naznačena time, da je namijenjena enzimskoj razgradnji biomase lignoceluloze i/ili za obradu tekstila i/ili kao sastojak u deterdžentima i/ili kao sastojak u hrani ili pripravcima stočne hrane.
The process in any of claims 1 to 6 wherein the high dilution factor in case of a sample in which the inhibitor bound form is negligible is at least 100 or at least 200, preferably at least 300 or at least 350 or highly preferably at least 400, the low dilution factor in case of a sample in which the active form is considered as negligible is at most 20 or at most 10 or highly preferably at most 5 or at most 4, and/or the ratio of dilution factors is thus at least 10 or preferably at least 30 or at least 70 or at least 100. 
Postupak prema patentnom zahtjevu 1 gdje visok faktor razrjeđivanja, gdje je zanemariv efekt ACE inhibitora, je najmanje 100 ili najmanje 200, poželjno najmanje 300 ili najmanje 350 ili veoma poželjno najmanje 400, i gdje referentni faktor niskog razrjeđivanja je najviše 20 ili najviše 10 ili veoma poželjno najviše 5 ili najviše 4, i/ili odnos faktora razrjeđivanja je tako najmanje 10 ili poželjno najmanje 30 ili najmanje 70 ili najmanje 100.
The resulting mixture is passed through a phase separation cartridge and the aqueous portion is acidified to pH 1-3 with 1M HCl. 
Dobivenu smjesu se pusti kroz umetak za rastavljanje faza i vodeni dio se zakiseli na pH 1-3 sl M HCI.
Other variations of the box are disclosed in FIG. 
Druge varijante kutije otkrivene su u SI.
Advantageously, the hyaluronic acid or a salt thereof in a method according to the invention is present in a solution. 
Postupak prema patentnom zahtjevu 1, naznačen time što hijaluronska kiselina ima prosječnu molekularnu težinu u rasponu od 50 000 do 10 000 000 Daltona.
Microcapsules according to claim 1 wherein the aliphatic isocyanate is a monomeric aliphatic isocyanate. 
Mikrokapsule prema patentnom zahtjevu 1, naznačene time, što je alifatični izocijanat monomerni alifatični izocijanat.
Alternatively, vacuum filter dryer, rotary vacuum dryer or air dryer can be used for drying donepezil hydrochloride hydrate. 
Alternativno se za sušenje donepezil hidroklorid hidrata može koristi i vakuumski filtar, vakuumsko rotacijsko sušilo ili zračno sušilo.
The catalyst according to claim 1, wherein the supported metal catalyst is a supported rhodium catalyst, a supported palladium catalyst, a supported platinum catalyst, a supported ruthenium catalyst or a supported iridium catalyst. 
Uporaba prema patentnom zahtjevu 5 ili 6, naznačena time što podržani metalni katalizator je podržani rodijev katalizator, podržani paladijev katalizator, podržani platinasti katalizator, podržani rutenijev katalizator ili podržani iridijev katalizator.
The pre-nozzle according to claim 9, characterized in that the angle of intersection is constant and greater than 0° in at least one region. 
Pred-mlaznica broda prema zahtjevu 9, okarakterizirana time da je kut križanja (27) konstantan 1 veći od 0* u barem jednom dijelu.
at least 51% of the cells in the population express on their surfaces detectable levels of CD178 (FAS ligand), 
(ili) najmanje 51 % stanica u populaciji na svojoj površini izražava uočljive razine CD178 (FAS ligand),
to 93% by weight in relation to the total weight of the self-adhesive matrix layer of at least one self-adhesive polymer selected from the group comprising polymers of acrylic or acrylate, and is comprised of monomers selected from the group comprising vinyl acetate, 2-ethylhexyl acrylate, butyl acrylate, acrylic acid, methyl methacrylate, methyl acrylate, tert-octyl acrylamide, 2-hydroxy ethyl acrylate, glycidyl methacrylate, or mixtures thereof; and 
do 20% po masi nikotina kao aktivne tvari. Naprava prema patentnom zahtjevu 1, naznačena time da samoljepljivi polimer jest akrilnog ili akrilatnog tipa te je izgrađen od monomera odabranih iz sljedeće skupine: vinil acetat, 2-etilheksil-akrilat, butil-akrilat, akrilna kiselina, metil-metakrilat, metil-akrilat, tert-oktilakrilamid, 2-hidroksietil-akrilat, glicidil-metakrilat ili njihove smjese.
A hemostatic porous composite sponge comprising a matrix of a biomaterial and ii) one hydrophilic polymeric component comprising reactive groups wherein i) and ii) are associated with each other so that the reactivity of the polymeric component is retained, wherein associated means that 
Hemostatska porozna kompozitna spužva koja se uglavnom sastoji od i) matrice biomaterijala i ii) jedne hidrofilne polimerne komponente koja sadrži elektrofilne reaktivne skupine, naznačena time da navedena hidrofilna polimerna komponenta je hidrofilno sredstvo za umrežavanje, pri čemu su i) i ii) međusobno povezani tako da je zadržana reaktivnost polimerne komponente, pri čemu izraz povezani znači da
is, optionally substituted aryl, heterocyclyl, or heteroaryl, wherein the optional substituents are selected from one or more of alkyl, halogen, hydroxy, trifluoroalkyl, OCF3, SO2alkyl, or alkoxy; 
R, je vodik, po izboru supstituirani alkil, alkenil, alkinil, cikloalkil, aril, heterociklil, heteroaril, aralkil, alkoksi, ariloksi, alkeniloksi ili alkiniloksi;
The lower organic layer was removed and the aqueous layer was extracted with dichloromethane (7.5 ml), the combined organic layers were concentrated under reduce pressure to ~5 ml. 
Donji organski sloj se ukloni, vodeni ekstrahira diklormetanom (7,5 ml), a pomiješane organske slojeve koncentrira pod sniženim tlakom do -5 ml.
Solar panel comprising a number of solar cells according to the preceding claims, wherein the solar cells are arranged electrically in series. 
Solarni panel koji sadrži veliki broj modula (1) solarnih ćelija u skladu sa prethodnim patentnim zahtjevima, gdje su moduli (1) solarnih ćelija električno raspoređeni u serijama.
A compound according to any one of 1 to 7, wherein the pharmaceutically acceptable salt is selected from the group consisting of the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzensulfonate, p-toluenesulfonate and pamoate. 
Spoj prema bilo kojem od prethodnih zahtjeva, naznačen time da je farmaceutski prihvatljiva sol odabrana iz skupine koju čine hidroklorid, hidrobromid, hidrojodid, nitrat, sulfat, bisulfat, fosfat, kiseli fosfat, izonikotinat, acetat, laktat, salicilat, citrat, tartrat, pantotenat, bitartrat, askorbat, sukcinat, maleat, gentisinat, fumarat, glukonat, HR P20170802 T1 glukaronat, saharat, format, benzoat, glutamat, metansulfonat, etansulfonat, benzensulfonat, p-toluensulfonat i pamoat.
The method of claim 26, wherein if the determination of no improvement is made in step (d), the therapeutically effective amount of the composition is increased. 
Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 17, naznačen time što ako se u koraku (d) odredi da nema poboljšavanja, terapijski djelotvornu količinu pripravka se poveća.
The wet crystals are directly used in the recrystallization which is described in examples 2-8. 
Vlažni kristali su direktno rabljeni u rekristalizaciji koja je opisana u primjerima 2-8. Primjer 2:
the first fragment comprises a first proximal end within a first repeat portion; 
(ili) proksimalni kraj prvog fragmenta se nalazi unutar prvog ponavljanog dijela;
In practice, with particular reference to the knitting shown in the accompanying figure, at least one stretch yarn, in the illustrated case a yarn 2a made of coated elastomer (for example Elastane), is dispensed at the first drop and at the third drop. 
U praksi, s posebnim osvrtom na pletivo prikazano na priloženoj slici, najmanje jedan rastezljiv konac, u prikazanom slučaju konac 2a, izrađen je od prevučenog elastomera (na primjer Elastana), i on dolazi s prvog transportera i s trećeg transportera.
wherein said potentiating agent is to be administered before said fusion protein and said fusion protein is to be administered without said potentiating agent following administration of said potentiating agent; 
pri čemu se navedeno sredstvo za pojačavanje daje prije navedenog fuzijskog proteina i navedeni fuzijski protein se daje bez navedenog sredstva za pojačavanje nakon davanja navedenog sredstva za pojačavanje;
A method of treating dementia associated with Parkinson's disease by improving or augmenting the effect of an acetylcholinesterase inhibitor comprising administering an effective daily dose of N-[2-(6-fluoro-1H-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzylamine or a pharmaceutically acceptable salt thereof to a patient in need of such treatment, wherein the effective daily dose administered to the patient is between about 30 and about 60 mg. 
HR P20182069 T1 PATENTNI ZAHTJEVI N-(2-(6-fluoro-1H-indol-3-iletil)-3-(2,2,3,3-tetrafluoropropoksi)benzilamin ili njegova farmaceutski prihvatljiva sol za uporabu u liječenju Alzheimerove bolesti poboljšavanjem ili povećavanjem efekta inhibitora acetilkolinesteraze koja sadrži primjenjivanje djelotvorne dnevne doze navedenog spoja pacijentu koji je u potrebi takvog liječenja, pri čemu djelotvorna dnevna doza primijenjena na pacijentu iznosi između 30 1 60 mg.
Adenosine aminohydrolase inhibitors such as Cladribine from Merck Serono. 
(Gi) Inhibitora adenozin aminohidrolaze kao što su Cladribine iz tvrtke Merck Serono.
The conjugate for use according to any one of claims 1 to 10 by treating a patient for a disease treatable by L-asparagine depletion, optionally wherein said disease treatable by L-asparagine depletion is a cancer, optionally wherein said cancer is selected from the group consisting of Acute Lymphoblastic Leukemia (ALL), non-Hodgkin's lymphoma, NK lymphoma, and pancreatic cancer. 
Konjugat za upotrebu prema bilo kojem od zahtjeva 1 do 10 za liječenje pacijenta od bolesti koje se liječe trošenjem L-asparaginaze, proizvoljno pri čemu je navedena bolest koja se liječi trošenjem asparaginaze rak, proizvoljno pri čemu je navedeni rak odabran iz skupine koju čine akutna limfoblastična leukemija (ALL), ne-Hodgkinov limfom, NK limfom i rak gušterače.
A compound of formula: and pharmaceutically acceptable salts, solvates and prodrugs thereof, wherein 
Spoj formule I: [image] i njegove farmaceutski prihvatljive soli i solvati, pri čemu
The organic portions are separated and washed with water (2 x 50 ml), brine (50 ml), dried (MgSO4) and concentrated in vacuo. 
Organski dijelovi se odvoje 1 isperu s vodom (2 x 50 ml, sa zas. otop. NaC1 (50 ml), osuše (MgSOy) 1 koncentriraju u vakuumu.
The particle size of the excipient will usually be much greater than the inhaled medicament within the present invention. 
Veličina čestice ekscipijensa obične je znatno veća od veličine čestica lijeka za inhaliranje sukladno predmetnom izumu.
wherein said multitude of administration units A is administered during a first administration interval of at least 2 days; said multitude of administration units B is administered during a second administration interval of at least 2 days following the first administration interval; and said multitude of administration units C is administered during a third administration interval of at least 2 days following the second administration interval. 
(iii) po izboru, mnoštvo jedinica za davanje C koje sadrže dozu c tapentadola, gdje so navedeno mnoštvo jedinica za davanje A daje tijekom prvog intervala davanja od najmanje 2 dana; navedeno se mnoštvo jedinica za davanje B daje tijekom drugog intervala davanja od najmanje 2 dana nakon prvog intervala davanja; i navedeno se mnoštvo jedinica za davanje C daje tijekom trećeg intervala davanja od najmanje 2 dana nakon drugog intervala davanja.
An inhaler according to claim 11, wherein at least one air bypass aperture extends through the partitioning wall to communicate the primary chamber with the secondary chamber. 
Inhalator prema zahtjevu 10, gdje se barem jedan otvor za prolaz zraka (35) pruža kroz razdjelni zid (33) radi komunikacije primarne komore (31) sa sekundarnom komorom (32).
The dissolution test employs a media of 7.2 pH phosphate buffer solution with 0.4 g/L sodium dodecyl sulfate (SDS, used to ensure wetting of the powders) at 37° C. and is carried out in USP Apparatus II (paddles) rotating at 50 RPM. The percentage of active pharmaceutical ingredient that is dissolved is measured over time. 
Postupak sukladno zahtjevu 1, naznačeno time, da aktivni farmaceutski sastojak potpuno oslobađa čestica farmaceutske formulacije za 30 minuta prema USP testu otapanja koristeći sredstvo 7.2 pH otopine fosfatnog pufera s 0.4 g/L natrijevog dodecil sulfata na 37*C u USP aparatu II pri 50 okretaja u minuti.